Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salbutamol, furosemide, and combination therapy for transient tachypnea of the newborn
ACTRN12624000987561Phase 3Not yet recruiting
- Sponsor
- Dr. Aamir Iqbal
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of salbutamol and furosemide in transient tachypnea of the newborn (TTN) (4 arms), sponsored by Dr. Aamir Iqbal. Primary endpoints: Time to resolution of transient tachypnea of the newborn symptoms and Duration of supplemental oxygen therapy. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
salbutamolfurosemide
03
Conditions
transient tachypnea of the newborn (TTN)
Beyond the preview
Go deeper on ACTRN12624000987561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000987561.